Hitachi High-Tech Corporation
Makes electron microscopes, metrology tools, and lab instruments used to build chips and diagnose disease.
A profitable, Hitachi-backed instrument maker whose main risk is the semiconductor spending cycle, not AI or a rival's product launch.
Hitachi High-Tech builds specialized equipment that semiconductor factories use to inspect and measure chips during production, plus analytical tools for labs and hospitals. It is hard to replace because factories have built their entire production lines around its machines over decades, regulators have approved it for medical use, and competitors like KLA and Applied Materials have not knocked it out. The big risk is that chip makers might buy less equipment if the industry slows down, which would directly hurt the company's sales and profits.
Hitachi High-Tech's FY2026 Q1 earnings (Aug 2026) order-book trend for semi-equipment. shows whether the semiconductor capex cycle is turning down, hitting revenue.
Further US BIS export-control actions targeting China after July 2026 and Hitachi's disclosed China revenue impact. shows how much policy risk is actually cutting into sales versus staying theoretical.
- FY2025 revenue: ¥821.7 billion
- CD-SEM cumulative units shipped: 6,000+
- FY2026 guidance: ¥875.0 billion revenue
- Semiconductor capex cyclicality; FY2025 growth explicitly tied to equipment order surge.
- US export controls tightened July 2026 restricting China sales of semiconductor equipment.
- Multi-year integration execution risk from April 2024 healthcare business company split.
- Nabsys/OhmX genomics platform remains early-stage commercially with uncertain clinical uptake.
- AI-driven defect-classification software layer could erode differentiation in inspection tools over time.
| Rival | Direction | Evidence |
|---|---|---|
| KLA Corporation | contesting | No displacement of HHT's CD-SEM franchise despite years of competing platforms, as of 2026-03-31 |
| Applied Materials | contesting | Adjacent semiconductor equipment maker; no qualified-fab share taken from HHT metrology as of 2026 |
| Thermo Fisher Scientific | contesting | Competes in analytical/life-science instrument segment across product lines |
| Averroes.ai (AI add-on vendor) | gaining on | Markets AI defect-detection layer for HHT's GS1000/GT2000/LS9300AD inspection tools, dated 2025-02-12 |
- Is Hitachi High-Tech profitable?
- Yes. For the fiscal year ended March 31, 2026, Hitachi High-Tech's Measurement & Analysis Systems business reported revenue of Y821.7 billion and Adjusted EBITA of Y102.6 billion, roughly a 12.5% margin, per Hitachi Ltd.'s April 27, 2026 consolidated results filing.
- Who owns Hitachi High-Tech?
- Hitachi High-Tech is a wholly owned subsidiary of Hitachi, Ltd. It was delisted from the Tokyo Stock Exchange in May 2020 after Hitachi completed a roughly Y531 billion tender offer to take full ownership, ending its independent public listing.
- Could AI replace Hitachi High-Tech's products?
- Unlikely for its core hardware. Its CD-SEM metrology tool holds a company-claimed ~70% global share with 6,000-plus units shipped as of March 2026, built on decades of fab qualification lock-in; AI mainly augments defect-classification software layered on top, not the physical instruments.
- Who is Hitachi High-Tech's biggest competitor?
- In semiconductor metrology and inspection it contests with KLA Corporation and Applied Materials, neither of which has displaced its CD-SEM franchise as of 2026. In analytical/life-science instruments it competes with Thermo Fisher Scientific, Agilent, and Shimadzu.
- Is it safe to take a job at Hitachi High-Tech?
- The company is backed by parent Hitachi Ltd (roughly $80B in revenue) and grew revenue about 22% from FY2023 (Y670.4B) to FY2025 (Y821.7B, reported April 27, 2026). Main risk is cyclicality: FY2025 growth was driven by a semiconductor equipment order surge that could reverse.
- How many employees does Hitachi High-Tech have?
- Per the company's own corporate data page, Hitachi High-Tech had 15,514 global employees across 25 countries and regions as of March 31, 2026, with an average employee age of 42.1 years.
- 2026-07-21Parent Hitachi launches HITPHAMS GMP drug manufacturing platform with generative AI defect detection
- 2026-07-09US Commerce Dept tightens export controls on semiconductor equipment aimed at China
- 2026-07-08Parent Hitachi announces HMAX Industry physical-AI plant-operation system
- 2026-05-17Nabsys announces new OhmX platform installations under HHT Americas RAMP UP program
- 2026-04-27FY2025 results: Y821.7B revenue, Y102.6B Adj. EBITA; FY2026 guidance Y875.0B/Y110.1B issued
- 2025-02-21OhmX RAMP UP grant awarded to 15 laboratories
- 2025-01Hitachi High-Tech Science Corporation rebranded to Hitachi High-Tech Analysis Corporation
- 2024-08-01Hitachi High-Tech closes acquisition of majority interest in Nabsys 2.0 LLC
- 2024-04-01Hitachi Ltd's Healthcare Business Division transferred into Hitachi High-Tech via company split
- 2020-05Delisted from Tokyo Stock Exchange via ~Y531B tender offer, becomes wholly owned Hitachi subsidiary
- Outline of Consolidated Financial Results for the Year Ended March 31, 2026 (2026-04-27)
- Hitachi High-Tech at a Glance (2026-03-31)
- Hitachi High-Tech Corporation
- Hitachi Announces Consolidation of Healthcare Business into Hitachi High-Tech through Company Split (2023-10-11)
- Hitachi High-Tech Acquires Majority Interest in Nabsys (2024-08-01)
- OhmX RAMP UP Grant Awarded to 15 Laboratories (2025-02-21)
- Nabsys Announces New OhmX Platform Installations (2026-05-17)
- Hitachi High-Tech Acquires Majority Interest in Nabsys (2024-08-01)
- Hitachi High-Tech Inspection Tools Review & Comparison (2025-02-12)
- Hitachi High-Tech Analysis Corporation
- Hitachi launches GMP drug manufacturing platform with generative AI (2026-07-21)
- Hitachi to launch HMAX Industry plant AI later this year (2026-07-08)